Clinical Trials Logo

Pneumococcal Conjugate Vaccine clinical trials

View clinical trials related to Pneumococcal Conjugate Vaccine.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03574389 Completed - Clinical trials for Pneumococcal Infections

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children

Start date: June 23, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and immunogenicity of 13-valent Pneumococcal conjugate vaccine in Chinese infant and young children.

NCT ID: NCT01646398 Completed - Clinical trials for Pneumococcal Vaccines

A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older

Start date: June 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine compared to a single dose of 23-valent pneumococcal polysaccharide vaccine in Japanese adults aged 65 years old and older.

NCT ID: NCT00918580 Completed - Clinical trials for Pneumococcal Conjugate Vaccine

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease

Start date: November 2009
Phase: Phase 3
Study type: Interventional

This study is to evaluate the safety, tolerability and immunogenicity of 13-valent pneumococcal Conjugate Vaccine in children with Sickle Cell Disease who have already been vaccinated with 23-valent polysaccharide vaccine. The study will measure the amount of antibodies (the proteins that fight off germs) produced by children with Sickle Cell Disease after they have been given the 13-valent pneumococcal vaccine between 6 and less than 18 years of age. They will be given the vaccination twice, each vaccination separated by approximately 6 months.

NCT ID: NCT00824850 Completed - Clinical trials for Pneumococcal Conjugate Vaccine

Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort

PILOT
Start date: January 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the "late" immune response to further doses of pneumococcal conjugate vaccine more than 10 years after primary immunization with Prevnar (7vPnC) in infancy, as compared with individuals who did not receive Prevnar in infancy (the Prevnar naive cohort which received MnCC). The study will take place at a single study center. Study participants must have participated previously in a specific Wyeth Prevnar study (Study D118-P8) and must still be enrolled in the Northern California Kaiser Permanente (NCKP) health plan.

NCT ID: NCT00688870 Completed - Vaccines Clinical Trials

Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan

Start date: June 5, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC) when given concomitantly with routine vaccines in Taiwan.